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Hyperglycaemia occurring in diabetes is responsible for accelerated arterial remodeling and atherosclerosis, aﬀecting the macro-
and the microcirculatory system. Vessel injury is mainly related to deregulation of glucose homeostasis and insulin/insulin-
precursors production, generation of advanced glycation end-products, reduction in nitric oxide synthesis, and oxidative and
reductive stress. It occurs both at extracellular level with increased calcium and matrix proteins deposition and at intracellular
level, with abnormalities of intracellular pathways and increased cell death. Peripheral arterial disease, coronary heart disease, and
ischemic stroke are the main causes of morbidity/mortality in diabetic patients representing a major clinical and economic issue.
Pharmacological therapies, administration of growth factors, and stem cellular strategies are the most eﬀective approaches and
will be discussed in depth in this comprehensive review covering the regenerative therapies of diabetic microangiopathy.
1. Introduction
Diabetes represents one of the greatest medical and socioeco-
nomic emergencies worldwide. Approximately 17.5 million
people have been diagnosed with diabetes in the USA and
their number is continuously growing by 1 million per year
[1]. Hyperglycaemia, occurring in type 1 (T1D) and type 2
diabetes (T2D), is responsible for a wide number of compli-
cations, with the vascular ones representing the leading cause
of morbidity and mortality in diabetic patients [2]. Acceler-
ated arterial remodeling, atherosclerosis, and endothelial cell
dysfunction, aﬀecting the macro- and the microcirculatory
system, are the main evidences and lead to progressive tissue
hypoperfusion and hypoxia [3]. In diabetes, multiple actors
concur in causing vascular remodeling, among them met-
abolic factors (e.g., hyperglycaemic and oxidative stress)
which are important for chemical and biological modifica-
tions of the extracellularmatrix, endothelial/vascular smooth
muscle cells, and mechanical factors (e.g., wall shear and
circumferential stress) due to the concomitant hypertension,
which cause enhanced inward remodeling, paralleled by
intima/media thickening, and attenuation of vessel dilation
[4, 5]. Moreover, hyperglycaemia and advanced glycation
end products (AGEs) have been shown to increase the matrix
surrounding endothelial cells and vascular smooth muscle
cells, increasing the deposition of proteins and the entrap-
ment of molecules and reducing metalloproteinases activity,
thus being responsible for impaired vessel dilation and wall
stiﬀening [6, 7]. Interestingly, the UK Prospective Diabetes
Study (UKPDS) andDiabetes Control of Complications Trial
(DCCT) have found microvascular disease and hypergly-
caemia intrinsically related [8]. Pharmacological therapies
with anti-inflammatory and anti-AGE/ROS drugs, angiogen-
esis inhibitors, administration of growth factors, either as
recombinant proteins or via gene transfer, and stem cellular
strategies are the most eﬀective approaches and will be
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Table 1: Role of β-cell replacement in the treatment of diabetic microangiopathic complications divided by site of pathology. Islet and
pancreas transplantation generally stabilize and in some cases improve the major diabetic complications in the long term. RAGE: advanced
glycation end products receptor.
Complication Pancreas transplantation Islet transplantation References
Ocular
Does not prevent diabetic retinopathy,
while the reversal is still controversial
Stabilization of retinopathy,
Increase in arterial and venous retinal
blood flow velocity
Ramsay et al. N Engl J Med,
1988 [9]; Lee et al. Transplant
Proc, 2005 [10]; Venturini et al.
Transplantation 2006 [11]
Renal
Reduction in the thickness of the
glomerular and tubular basement
membranes,
Decreased urinary albumin excretion
Retarded progression of diabetic
nephropathy,
Decreased urinary albumin excretion
survival of the kidney graft
Fioretto et al. N Engl J Med,
1998 [12] and Lancet, 1993
[13]; Fiorina et al. J Am Soc
Nephrol, 2003 [14]
Neurological
Progressive improvement of nerve
conduction velocity
Positive impact on polyneuropathy,
Reduce nerves’ RAGE expression,
Conservation of perineurium and vasa
nervorum
Kennedy et al. N Engl J Med,
1990 [15]; Del Carro et al.
Diabetes Care, 2007 [16]
Cardiovascular
Positive eﬀects on atherosclerosis
coronary and carotid intimal thickness
reduction
Peripheral vascular disease can worsen
Reduction in carotid intima media
thickness
Stabilization of microangiopathy in skin
biopsies
Improved dyastolic function
Reduced hemostatic abnormalities
Fiorina et al. Diabetes Care,
2005 [17], Del Carro et al.
Diabetes Care 2007 [16]; Larsen
et al. Diabetes Care, 2007 [18]
discussed in depth in this comprehensive review covering the
regenerative therapies of diabetic microangiopathy.
2. β-Cell Replacement
Subcutaneous daily insulin injections improve glycometa-
bolic control and HbA1c% levels; however they are not able
to entirely halt the occurrence of diabetic complications [13].
β-cell replacement, either pancreas or islet transplantation, is
a life-saving intervention which can restore normoglycaemia
[19].
2.1. Pancreas Transplantation. Despite being a procedure still
aﬀected by major risks, pancreas transplantation, when suc-
cessful, leads to an immediate insulin withdrawal, as the
newly transplanted pancreas is capable to secrete insulin im-
mediately after the revascularization, normalizing HbA1c%
levels in the long term (up to 10 years) [20]. Diabetic re-
tinopathy is the most frequent diabetic complication with at
least 75% of patients with T1D developing the disease by 10
years and 40% of them degenerating into blindness within 3
years [21]. Studies performed in diabetic patients receiving
pancreas or kidney-pancreas transplantation have shown
that the normoglycaemia achieved with these approaches
do not prevent or reverse diabetic retinopathy [9] (Table 1).
Conversely, Wang et al. reported regression of diabetic neph-
ropathy at 1 year in 43% of simultaneous kidney-pancreas-
transplanted subjects [22]. In general, it has been shown that
pancreas transplantation halts the progression of diabetic
nephropathy [13, 23, 24] (Table 1). Studies performed on
pancreas-transplanted patients have shown that diabetic
glomerular lesions aﬀecting their own kidneys prior to trans-
plantation were not ameliorated by 5 years of normo-
glycaemia, while an improvement was observed after 10
years [12, 13] (Table 1). Diﬀerent studies have shown that
neuropathy progression (and the associated vascular degen-
eration) can be halted by successful pancreas transplantation
[15, 25, 26]. Martinenghi et al. reported that progressive
amelioration of nerve conduction velocity was prominently
related to the pancreas graft, given that in a cohort of kidney-
pancreas-transplanted patients, the failure of the pancreas,
that occurred at least 2 years after successful combined
transplantation, was associated with a deterioration of nerve
conduction velocity back to pretransplant levels [27]. Coro-
nary intimal thickness has been reported to regress in 40%
of transplanted patients, as well as carotid atherosclerotic
plaques have been seen to improve within 2 years after pan-
creas transplantation [28].
2.2. Islet Transplantation. Islet transplantation is a new con-
cept β-cell replacement alternatively employed to pancreas
transplantation in selected groups of patients suﬀering from
severely poor glycaemic control and recurrent hypogly-
caemic episodes, especially if associated with reduced hypo-
glycaemic awareness [8]. Lee et al. reported a stabilization of
retinopathy in islet transplanted patients in some cases even
at 1 year after transplant [10]. Venturini et al. investigated
through color-Doppler-imaging the blood flow of the central
retinal arteries in a group of islet-transplanted patients,
before and at 1 year after transplantation, and found a signi-
ficant increase in arterial and venous retinal blood flow velo-
cities in transplanted patients compared to the control group
[11] (Table 1). Islet transplantation is often performed in dia-
betic patients who have already experienced a kidney trans-
plant due to end-stage renal disease; however, no unique
interpretation about islet transplantation role on kidney graft
function has been reached so far. Our group showed that in
T1D patients islet transplantation is able to improve kidney
graft survival and function, also decreasing microalbumin-
uria [14] (Table 1). Lee et al. studied the peripheral nerve
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function of islet transplanted patients demonstrating that
β-cell replacement has a positive impact on polyneuropathy
as well [10]. Accordingly, Del Carro et al. showed that islet
transplantation may stabilize or even improve polyneu-
ropathy by reducing AGE receptors (RAGEs) expression in
formerly kidney-transplanted T1D patients [16] (Table 1). In
the same work, skin biopsies from islet-transplanted patients
showed a higher conservation degree of perineurium and
vasa nervorum compared to end-stage renal disease and
kidney-transplanted T1D subjects [16]. In a previous work,
we similarly demonstrated that skin biopsies performed in
successful islet transplanted patients, showed a stabiliza-
tion of diabetic microangiopathy after 3 years of follow-up,
with an increased expression of endothelial nitric oxide and
von Willebrand factor, associated with a reduction of capil-
lary basement membrane thickness and endothelial cellular
swelling [17] (Table 1).
3. Pharmacological Therapies
3.1. Anti-Inflammatory Drugs. High glucose concentrations
induce the production of the proinflammatory cytokine IL-
1 in human pancreatic β-cells, contributing to impaired
insulin secretion and β-cell proliferation [29]. In a random-
ized double-blind, trial, anakinra (a recombinant human IL-
1 receptor antagonist) reduced HbA1c% and IL-6 concen-
tration increasing C-peptide secretion in T2D patients [18].
Recent studies suggested that anti-inflammatory drugs may
have an important role in diabetes therapy. The administra-
tion of salsalate (a prodrug carrying fewer side eﬀects than
aspirin) for a period of 2–4 weeks in T2D patients was able to
reduce glucose blood concentrations while increasing insulin
secretion [30–34]. Pentoxifylline is an anti-inflammatory
methyl-xanthine derivative which is currently studied in
a number of clinical trials evaluating its role in diabetic
patients with nephropathy. It has been shown to significantly
decrease proteinuria in both T1D and T2D patients; however
given the small number of patients and the short duration
of the studies, additional research is required to determine
whether long-term use of pentoxifylline could be considered
for the prevention or treatment of diabetic complications
[35, 36]. Finally, it is becoming more and more evident that
conventional therapies for diabetes are eﬀective in reducing
inflammation and improving diabetes outcomes via indirect
or pleiotropic mechanisms. In fact, lifestyle modifications
promoting weight loss, caloric restriction, and physical ex-
ercise, together with metformin and statin therapy, have
recently been shown to reduce high C reactive protein levels
in T2D patients [37, 38].
3.2. PKC Inhibitors. Hyperglycaemia is a fundamental meta-
bolic factor involved in the development of both micro- and
macrovascular complications, having numerous adverse
eﬀects such as the chronic activation of protein kinase C
(PKC), a family of enzymes profoundly involved in the con-
trol of multiple cellular pathways [39]. Diﬀerent PKC iso-
forms (PKC-α, -β1/2, and PKC-δ) have been shown to be
associated with vascular alterations such as modifications
of permeability, angiogenesis, synthesis of the extracellular
matrix, cell growth/apoptosis, leukocytes migration, and
cytokines production, thus leading to pathologies aﬀecting
the macrovasculature (atherosclerosis, cardiomyopathy) and
the microvasculature (retinopathy, nephropathy, and neu-
ropathy) [40]. Both preclinical and clinical studies using
PKC-β inhibitors have been carried out, obtaining encour-
aging results. The PKC-β inhibitor ruboxistaurin (LY333531,
RBX/Arxxant; Eli Lilly and Company, Indianapolis, IN) was
employed in murine models of diabetes with virtually no
eﬀect on HbA1c%, blood glucose level, or blood pressure,
however leading to normalization of glomerular filtration
rate (GFR), urinary albumin, and TGF-β1 excretion and also
reducing the glomerular and mesangial extracellular matrix
[41, 42]. A multicenter pilot study evaluated the eﬀect of
LY333531 (32mg/day) in T2D patients aﬀected by diabetic
nephropathy in addition to their current therapy with angio-
tensin-converting enzyme inhibitors and angiotensin recep-
tor blockers, showing a 25% reduction in urinary albumin
creatinine ratio (ACR) after 1 year and a conservation of the
estimated GFR level [43]. The PKC-β inhibitor diabetic reti-
nopathy study (PKC-DRS) reported a lower incidence of
visual loss, need for laser treatment, and macular oedema
progression in T1D and T2D patients treated with 32mg/day
LY333531 for 36–46 months [44, 45]. Inhibition of PKC-β
through LY333531 is also beneficial to patients with symp-
tomatic diabetic neuropathy, improving sensory symptoms
and vibration sensation [46, 47]. A phase II multinational
pilot study assessed the eﬀect of LY333531 (32 or 64mg/day
for 1 year) in patients with diabetic neuropathy demonstrat-
ing a significant reduction of total symptoms and improve-
ment at the vibration detection threshold [48]. Treatment
with LY333531 (32mg/day for 7 days) has been shown to
prevent endothelium-dependent vasodilation abnormalities
induced by hyperglycaemia as well [49].
3.3. AGEs and Oxidative Stress Strategies. Diabetes is charac-
terized by abnormalities of mitochondrial ROS production
that generate an increased oxidative stress in endothelial
cells thus causing the development of diabetes complications
[50]. In physiologic ageing AGEs can target proteins forming
irreversible complexes that become resistant to proteolytic
degradation; however, in the diabetic state the process results
accelerated [51]. Aminoguanidine, scavenging intermediates
in the glycation catalytic process, inhibits the formation of
AGEs slowing the progression of diabetic nephropathy [52];
however the first clinical study performed in T1D patients
with nephropathy and retinopathy, beside recording a con-
sistent reduction of proteinuria, reported retinopathy wor-
sening in some treated patients compared to placebo [53].
Vitamins of the B group represent another approach for
the reduction of AGEs-related complications [54]. Preclinical
studies revealed that pyridoxamine is eﬀective in preserving
kidney function in T1D and T2D murine models [54]. Con-
sistently phase II clinical trials in proteinuric T1D and T2D
patients showed a significant decrease in serum creatinine
level, albumin, and TGF-β urinary excretion. An ongoing
phase IIb study (http://clinicaltrials.gov/, NCT00734253) is
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evaluating the safety and eﬃcacy of pyridoxine in nephro-
pathic T2D patients. Finally, another clinical trial (http://
clinicaltrials.gov/, NCT00565318) is now assessing the eﬀect
of benfotiamine, a lipophilic analogue of thiamine (B1 vita-
min), on urinary albumin and β2-microglobulin excretion
in T2D patients. Another class of therapeutic agents useful
in reducing AGEs accumulation is advanced glycation cross-
link breakers. Recently TRC4186 has been shown to decrease
albuminuria and improve kidney function in diabetic mice
with progressive cardiac and kidney failure, but 2-week
treatment with ALT-711 (alagebrium), a novel AGE breaker
compound had no eﬀects on motor/nociceptive nerve dys-
function and vascular stiﬀness in diabetic mice after 8 weeks
of diabetes [55, 56]. A clinical trial evaluating the eﬀect of
alagebrium (200mg twice daily) on diabetic nephropathy
(http://clinicaltrials.gov/, NCT00557518) reported a de-
crease in arterial pulse pressure and an increase in endothelial
function and artery compliance [57, 58].
3.4. Inhibitors of Angiogenesis. Vascular endothelial growth
factor (VEGF) is overproduced in the diabetic retina in res-
ponse to capillary loss and/or microaneurysm formation;
thus inhibition of VEGF activity may play a pivotal role
in the prevention of diabetes-related retinopathy [59]. Cur-
rently, there are three main anti-VEGF agents under investi-
gation: pegaptanib sodium, a pegylated RNA aptamer that
binds VEGF165 and the longer VEGF isoforms (Macugen;
Eyetech Pharmaceuticals Inc, New York, and Pfizer Inc, NY);
ranibizumab, a recombinant humanized monoclonal anti-
body specific for all human VEFG isoforms (Lucentis; Gen-
entech Inc, South San Francisco, CA), and bevacizumab,
another full-length humanized monoclonal antibody against
all isoforms of human VEGF (Avastin; Genentech, South San
Francisco, CA) [60]. VEGF has a role in the pathogenesis of
diabetic nephropathy as well. SU5416 by selectively blocking
all VEGF receptors at the level of the tyrosine kinase has been
reported to ameliorate albuminuria in an experimental
model of diabetic nephropathy [61]. In preclinical studies
ruboxistaurin attenuated the eﬀect of VEGF and so the prog-
ression of diabetic nephropathy [62].
4. Cellular Therapies
Stem cells have the unique ability to potentially originate any
organ or tissue, being undiﬀerentiated and capable of self-
renewal [63]. Stem cells can be obtained from embryos, um-
bilical cord blood, and adult tissues (as bone marrow or
adipose tissue) [63].
4.1. Cord Blood Stem Cells. Cord blood stem cells (CB-SCs)
are a heterogeneous population composed of (i) very small
embryonic-like stem cells, (ii) mesenchymal stem cells
(MSCs), (iii) hematopoietic stem cells, and (iv) endothelial
progenitor cells (EPCs) [63]. CB-SCs are easily collectable
from 60–80 cc of umbilical cord blood and exhibit common
features like the presence of long and highly preserved telo-
meres, the ability to form colonies when cultured in vivo, and
a virtually absent oncogenic potential [63, 64]. An exper-
imental study performed by Naruse et al. highlighted the
therapeutic role for ex vivo expanded CB-EPCs in the treat-
ment of diabetic neuropathy, showing that hind limb EPCs
intramuscular injection into streptozotocin- (STZ-) induced
diabetic rats improved muscles microvascular net, sciatic
nerve conduction velocity, and endoneurial nutritive blood
flow [65] (Table 2). Additionally, a clinical trial evaluating
safety and eﬃcacy of allogeneic CB-MSCs injections into
pathologic lower limbs of T2D patients aﬀected by periph-
eral arterial disease is currently ongoing at the Stem Cell
Research Center at Qingdao University, (http://clinicaltrials
.gov/, NCT01216865).
4.2.Mesenchymal StemCells. Among stem cells, great clinical
interest is reserved to MSCs. Beside their potential to dif-
ferentiate [66, 67], MSCs are characterized by strong hypo-
immunogenic features, such as low expression of MHC-I-
related antigens and absence of MHC-II antigens [68],
making these cells immune privileged [69–77] (e.g., MSCs
neither induce CD4+ activation nor are subjected to cell lysis
induced by cytotoxic lymphocytes [78]). Moreover, MSCs
are able to exert anti-inflammatory actions, for instance, by
decreasing the secretion of TNF-α by dendritic cells [76, 77].
In a murine model of diabetic cardiomiopathy, Zhang et al.
evaluated the ability of intravenous administration of BM-
MSCs to either promote angiogenesis and mitigate ventricu-
lar remodeling, reporting an increased number ofmyocardial
arterioles, an improvement of cardiac functionality, and a
decrease of metalloproteinases activity, with a consequent
smoothing of heart remodeling [79] (Table 2). Additionally,
Wu et al. showed that allogeneic transplantation of BM-
MSCs significantly promoted wound healing in diabetic
db/dbmice by accelerating reepithelialization and reconstitu-
ting capillary network density [80] (Table 2). Finally, Yang
et al. showed that adipose-derived MSCs infusion in an
STZ-induced murine model of diabetic retinopathy reduced
blood glucose level and blood retinal barrier damage [81]
(Table 2).
4.3. Endothelial Progenitor Cells. EPCs are circulating cells
originating from several tissues such as bone marrow, peri-
pheral blood, and cord blood, which are able to generate
mature endothelial cells and vascular structures [82]. Thanks
to their involvement in angiogenic and vasculogenic pro-
cesses [82–86], EPCs represent an additional powerful tool
for the treatment of diabetic microvascular complications.
Interestingly, Barcelos et al. showed that human fetal aorta
CD133+ progenitor cells, when transplanted into a murine
model of diabetic wound, are either able to promote angio-
genesis and to release VEGF-A in a high-frequency fashion
[87]. Fiorina et al. demonstrated that the mobilization of
endogenous BM-EPCs to the site of wound in amousemodel
of diabetic wound healing is improved by the targeting of
CXCR4/CXCL12 axis through a CXCR4 antagonist [88]. A
currently ongoing phase I clinical trial is evaluating the effi-
cacy and safety of the administration of AMD3100 (Plerixa-
for) and rhPDGF-BB (Becaplermin), two novel agents able
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Table 2: Overview of the experimental studies describing the role of stem cells in diabetic microangiopathy treatment and prevention. AD:
adipose derived; BM: bone marrow; CB: cord blood; EPCs: endothelial progenitor cells; MSCs: mesenchymal stem cells; BRB: blood retinal
barrier.
Complication Cells Outcomes References
Neurological CB-EPCs
Increased number of microvessels,
Improved sciatic motor nerve conduction velocity,
Increase of sciatic endoneurial nutritive blood flow
Naruse et al. Diabetes, 2005 [65]
Cardiovascular BM-MSCs
Enhanced number of myocardial arterioles,
Increase in fractional shortening,
Mitigation of heart remodeling.
Zhang et al. Exp Clin Endocrinol
Diabetes, 2008 [79]
Wound Healing BM-MSCs
Acceleration of wounds healing,
Increase in capillary density.
Wu et al. Stem cells, 2007 [80]
Ocular AD-MSCs Repair of BRB damages
Yang et al. Graefes Arch Clin Exp
Ophthalmol, 2010 [81]
Wound Healing BM-EPCs Promotion of neovascularization. Asai et al. Circulation, 2006 [89]
Neurological BM-EPCs
Restoring of nerve conduction velocity,
Increased blood flow in sciatic nerve,
Increased nerves capillary density.
Jeong et al. Circulation, 2009 [90]
to mobilize endogenous BM-EPCs, for the treatment of
peri-pheral arterial disease in T2D patients, (http://clinical-
trials.gov/, NCT01353937). Recently, Asai et al. demon-
strated that Sonic Hedgehog (SHh, a protein that stimulates
BM-EPCs proliferation/migration and VEGF production,
promoting the neovascularization of ischemic tissues) was
responsible for wound healing acceleration in db/db mice
by enhancing angiogenesis and recruiting BM-EPCs into the
wound [89] (Table 2). Jeong et al. reported that hind limb
BM-EPCs infusion was able to reverse diabetic neuropathy
in STZ-induced diabetic mice, improving sciatic nerve con-
duction velocity and blood flow, compared to saline treated
controls [90] (Table 2). Finally, transplanted BM-EPCs ex-
hibited homing attitudes to the sciatic nerve and its vasa ner-
vorum, also reporting a paracrine activity realized through
the release of either angiogenic and neurotrophic factors [90]
(Table 2).
5. Gene Therapy
Growth factors administration by gene transfer is a promis-
ing approach for the treatment of diabetic microangiopathy,
promoting endothelial cell proliferation, migration, and
blood vessel formation.
5.1. Vascular Endothelial Growth Factor. VEGF is an endo-
thelial-specific growth factor that promotes endothelial cells
proliferation, diﬀerentiation, and survival, mediates endo-
thelium-dependent vasodilation, induces microvascular hy-
perpermeability, and participates in interstitial matrix re-
modeling [91]. Notably, at low concentration VEGFs are
mostly vasculoprotective, at high concentration have angio-
genic eﬀects, whereas at sustained high dose cause patholog-
ical angiogenesis [91]. VEGF-A, particularly its 165 isoform,
plays a major role in vascular biology and is the first can-
didate for therapeutic applications in vivo [92, 93]. Isner et al.
first demonstrated the tolerability of plasmid injection trans-
ferring a human VEGF165 encoding plasmid (ph) in patients
with peripheral arterial disease [94, 95]. The safety and
beneficial results of phVEGF165 were reported as well by Shyu
et al. in patients with critical limb ischemia (CLI) [96]. Sim-
ilarly, intramuscular phVEGF165 was tested in ischemic neu-
ropathic patients [97]; however, no relevant biologic eﬀects
were obtained due to the partial ineﬃciency of VEGF gene
transfer [98]. Conversely, a phase I study demonstrated the
major eﬃciency of adenoviral (Ad) vector in VEGF121 trans-
fer in severe vascular disease patients, showing an increase
of lower-extremity flow reserve in response to acetylcholine
[99]. Less optimistic outcomes were shown in other studies
where Ad.VEGF121 administration in patients with intermit-
tent claudication was not associated with an improvement in
exercise performance and quality of life, and similarly, treat-
ment with Ad.VEGF165 did not reduce the rate of amputation
events [100] (Table 3).
5.2. Fibroblast Growth Factors. Fibroblast growth factor
(FGFs) is a large family of proteins capable of modulating the
proliferation and migration of endothelial cells, fibroblasts,
and smooth muscle cells [101]. FGF-1 is a potent mitogen
for vascular cells and induces the formation of mature blood
vessels in vivo. In 2007, Sanofi-Aventis started a promising
trial (currently ongoing) based on the gene transfer of FGF-1
plasmid DNA in patients with CLI, known as TAMARIS
(Therapeutic Angiogenesis for the Management of Arteri-
opathy in a Randomized International Study) [102], aiming
at evaluating the eﬃcacy and safety of intramuscular admin-
istration of NV1FGF in CLI patients, a plasmid-based gene
delivery system for the local expression of FGF-1 [103, 104]
(Table 3). After 1 year of follow-up, the primary endpoint
of major amputations or death occurrence did not diﬀer be-
tween the treated and the placebo arm [105]. FGF-4 has been
shown to stimulate endothelial cells proliferation, migration,
and neovascularization in vivo by upregulating endogenous
VEGF-A expression [106]. Indeed, a currently ongoing clin-
ical trial is evaluating the therapeutical potential of VEGF-
A165/basicFGF delivery in the myocardium of refractory
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Table 3: Role of gene transfer in the treatment of diabetic microangiopathy. Gene transfer promotes endothelial cell proliferation, migration,
and blood vessel formation. VEGF: vascular endothelial growth factor; FGF: fibroblast growth factor; HGF: hepatocyte growth factor; HIF-
1α: hypoxia inducible factor-1α.
Study Year Identifier Site Status/recruited pts
VEGF
Vegf gene transfer for critical limb
ischemia
2010 NCT00056290
Steward St. Elizabeth’s
Medical Center of
Boston
Completed
VEGF gene transfer for diabetic
neuropathy
2010 NCT00056290
Steward St. Elizabeth’s
Medical Center of
Boston
Completed
Angiogenesis using VEGF-A165/bFGF
plasmid delivered percutaneously in
no-option CAD patients; a controlled
trial (VIF-CAD)
2009 NCT00620217
Institute of Cardiology,
Warsaw, Poland
Completed
FGF
Eﬃcacy and safety study of NV1FGF in
patients with severe peripheral artery
occlusive disease (TALISMAN202)
2010 NCT00798005 Sanofi-Aventis Completed
Eﬃcacy and safety of
XRP0038/NV1FGF in critical limb
ischemia patients with skin lesions
(TAMARIS)
2010 NCT00566657 Sanofi-Aventis
This study is ongoing, but not
recruiting participants
HGF
Study of hepatocyte growth factor
(HGF) via plasmid vector to improve
perfusion in critical limb ischemia
patients with peripheral ischemic ulcers
2011 NCT00189540 AnGes This study has been completed
HIF
Safety and eﬃcacy study of
Ad2/Hypoxia inducible factor-1α
(HIF-1α)/VP16 gene transfer in patients
with intermittent claudication (WALK)
2010 NCT00117650 Genzyme This study has been completed
coronary artery disease patients [102]. So far, most eﬀorts
have concentrated on a single gene delivery therapy; however
as multiple proteins are involved in the angiogenic process,
eﬃciently delivering more than one gene might be a valuable
approach [106].
5.3. Hepatocyte Growth Factor. Hepatocyte growth factor
(HGF) is a large protein first identified as a potent hepatocyte
mitogen and only lately discovered to stimulate endothelial
cells growth [107]. Preclinical studies have shown that the
delivery of HGF as a recombinant protein or naked plasmid
induces therapeutic angiogenesis in rat or rabbit peripheral
arterial disease models [108, 109]. Similarly, muscular injec-
tion of naked human HGF plasmid resulted in increased
blood flow in the same models [109]. Following these precli-
nical results, the safety and eﬃcacy of HGF plasmid adminis-
tration was investigated in patients with CLI, evaluating limb
tissue perfusion by transcutaneous oxygen tension measure-
ment and reporting higher values of oxygen tension at 6
months as compared to controls [110] (Table 3).
5.4. Hypoxia-Inducible Factor-1. Hypoxia-inducible factor-1
(HIF-1) is a mesenchyme-derived pleiotropic transcriptional
activator that acts as a regulator of oxygen homeostasis [111].
HIF-1 is a heterodimer composed of a constitutively ex-
pressed HIF-1β subunit and a O2-regulated HIF-1α subunit,
with the latter increasing at low oxygen levels [111]. The
complex of HIF-1β/α regulates the expression of many
genes, including VEGF [111]. The injection of plasmid DNA
encoding HIF-1α stimulates the recovery of blood flow in
hind limb ischemia animal models [112, 113]. Similarly,
intramuscular injection of adenovirus encoding functional
HIF-1α in a murine model of hind limb ischemia increased
the recovery of limb perfusion [113]. Finally, intramuscular
injection of escalating dose of adenoviral HIF-1α-VP16 in
patients with CLI has shown tolerability and safety [114]
(Table 3).
5.5. Nerve Growth Factor. Recently, nerve growth factor
(NGF) has been discovered to have cardiovascular protective
roles and angiogenetic capabilities [115]. For these reasons, it
is becoming particularly appealing for the treatment of dia-
betes vascular complications. Emanueli et al. strikingly intro-
duced the concept of neurotrophins, particularly NGF, as
autocrine proangiogenetic factors, promoting the growth of
new capillaries and accelerating blood flow recovery in is-
chemic muscles of a mouse model of limb ischemia [116]. In
fact, NGF seems to induce angiogenesis by increasing the
expression level of VEGF-A and VEGF receptors [116, 117]
and also by promoting NO production and metallopro-
teinases upregulation [116, 118]. Accordingly, Meloni et al.
translated these findings into a gene therapy approach for the
prevention of diabetic cardiomyopathy in a murine model
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of diabetes [119]. After 2 weeks of diabetes, mice were treated
with NGF gene transfer via adenoassociated viral vectors
[119]. Treatedmice were found to be protected frommyocar-
dial microvascular rarefaction, hypoperfusion, increased
deposition of interstitial fibrosis, and increased apoptosis of
endothelial cells and cardiomyocytes [119].
5.6. Kallikreins. Kallikreins can be divided in tissue and
plasma kallikreins diﬀering in molecular weight, substrate
specificities, and type of kinin released. Tissue kallikrein is
a glycoprotein that stimulates cells to release autacoids such
as nitric oxide and prostaglandins [120]. Circulating tissue
kallikrein levels are increased in patients with peripheral ob-
structive vascular disease and in skeletal muscle after the
induction of hind limb ischemia [121]. The angiogenic po-
tential of tissue kallikrein in peripheral ischemia has been
established in preclinical models using a gene-transfer ap-
proach [122]. Replication-defective adenoviral vector con-
taining the human tissue kallikrein gene was injected into the
adductor skeletal muscle of mice submitted to unilateral limb
ischemia [123]. The successful transduction of the transgene
resulted in ameliorated angiogenic response and haemody-
namic recovery [123]. Emanueli et al. have also documented
that human tissue kallikrein is able to prevent diabetic micro-
angiopathy in STZ-induced diabetic murine models [124].
6. Conclusions
Multidisciplinary management of diabetes is of outstanding
importance for the treatment and the prevention of diabetic
complications, being helpful in reducing social costs and
the detriment to the patient; however newer therapeutic
approaches are needed. Novel mechanistic insights in the
pathogenesis of endothelial dysfunction are rapidly being
translated into new therapeutic opportunities; stem cells are
expected to become promising therapeutic agents for dia-
betic patients due to their immunomodulatory characteris-
tics, self-renewal, and diﬀerentiation ability; many clinical
trials are demonstrating gene therapy as a valuable option
to treat peripheral arterial disease. Nonetheless, gene therapy
together with the cellular one is still waiting for randomized
placebo-controlled double-blind, large-scale, clinical trials,
ultimately defining their clinical role. Despite only short- and
midterm follow-up data are available and long-term safety
and eﬃcacy end-points are required, some of these new strat-
egies are close to become established therapeutic options,
and some others hold in them the potential to halt diabetic
complications.
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